Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

Article

February 1, 2005

New target, intervention for treating melanoma

Boston — New research discoveries demonstrate that melanoma is highly dependent on cyclin-dependent kinase 2 (CDK2) for growth and proliferation. Inhibiting expression of the gene regulating CDK2 stops the cancer dead in its tracks.

Related Videos

Melinda Gooderham, MD, MSc, FRCPC: Reaffirming Delgocitinib Safety With Minimal Absorption, Maximum Confidence

Quality of Life Impact: Supporting Patients With GPP

The Challenges of Diagnosis and Management of GPP

Melinda Gooderham, MD, MSc, FRCPC: Minimal Systemic Exposure of Delgocitinib Cream in Chronic Hand Eczema

Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies

Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists

Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability

Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis

Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma